Literature DB >> 16377272

Prognostic implications of a normal stress technetium-99m-tetrofosmin myocardial perfusion study in patients with a healed myocardial infarct and/or previous coronary revascularization.

Arend F L Schinkel1, Abdou Elhendy, Jeroen J Bax, Ron T van Domburg, Aukje Huurman, Roelf Valkema, Elena Biagini, Vittoria Rizzello, Harm H Feringa, Eric P Krenning, Maarten L Simoons, Don Poldermans.   

Abstract

Previous studies have shown a good outcome for patients who present with normal findings on stress myocardial perfusion imaging. Currently, the prognostic implications of a normal study in patients who have a history of coronary artery disease (CAD) are not clear. This study investigated the long-term prognosis after a normal finding on stress technetium-99m (Tc-99m)-tetrofosmin single-photon emission computed tomography in patients with a history of CAD. The study included 147 consecutive patients with a history of CAD (previous myocardial infarction and/or myocardial revascularization), who underwent exercise bicycle or high-dose dobutamine-atropine stress Tc-99m-tetrofosmin single-photon emission computed tomography, and had normal perfusion results during stress and at rest. Follow-up was completed in all patients. During a follow-up of 6.5 +/- 1.9 years, 20 patients (14%) died, 10 (7%) of whom died due to cardiac causes, and 12 (8%) had a nonfatal myocardial infarction. Annual cardiac death rates were 0.5% during the first 3 years of follow-up and 1.3% in the subsequent 3 years. Independent predictors of cardiac death were male gender, rate-pressure product at rest, and rate-pressure product at peak stress. In conclusion, patients who have a history of CAD have a very low cardiac death rate during the 3 years after a normal finding on stress Tc-99m-tetrofosmin single-photon emission computed tomography. Repeated testing should be reconsidered 3 years after the initial evaluation and when a change in symptoms or clinical condition occurs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377272     DOI: 10.1016/j.amjcard.2005.07.102

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Multiple testing, cumulative radiation dose, and clinical indications in patients undergoing myocardial perfusion imaging.

Authors:  Andrew J Einstein; Shepard D Weiner; Adam Bernheim; Michal Kulon; Sabahat Bokhari; Lynne L Johnson; Jeffrey W Moses; Stephen Balter
Journal:  JAMA       Date:  2010-11-15       Impact factor: 56.272

2.  Nuclear cardiology in the literature.

Authors:  Kenneth A Brown
Journal:  J Nucl Cardiol       Date:  2006-07       Impact factor: 5.952

3.  Warranty periods for normal myocardial perfusion stress SPECT.

Authors:  Guillermo Romero-Farina; Jaume Candell-Riera; Santiago Aguadé-Bruix; Ignacio Ferreira-González; Gemma Cuberas-Borrós; Nazarena Pizzi; David García-Dorado
Journal:  J Nucl Cardiol       Date:  2014-08-13       Impact factor: 5.952

4.  Prognostic estimation of coronary artery disease risk with resting perfusion abnormalities and stress ischemia on myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Robert C Hendel; Gary V Heller; Salvador Borges-Neto; Manuel Cerqueira; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2008-09-12       Impact factor: 5.952

5.  Predictive variables for hard cardiac events and coronary revascularization in patients with normal left ventricular myocardial perfusion and systolic function.

Authors:  Guillermo Romero-Farina; Jaume Candell-Riera; Santiago Aguadé-Bruix; Gemma Cuberas-Borrós; Ignacio Ferreira-González; María Nazarena Pizzi; Gustavo de León; Alba Santos; David García-Dorado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

6.  Influence of 99mTc-tetrofosmin SPECT myocardial perfusion imaging on the prediction of future adverse cardiac events.

Authors:  Diwakar Jain; Harry Lessig; Riti Patel; Leonard Sandler; Fred Weiland; Steven L Edell; M Elizabeth Oates; Erin O'Malley-Tysko; Natalie Khutoryansky; Arnold F Jacobson
Journal:  J Nucl Cardiol       Date:  2009-04-24       Impact factor: 5.952

7.  Higher event rate in patients with known CAD despite a normal myocardial perfusion scan.

Authors:  Maseeh Uz Zaman; Nosheen Fatima; Unaiza Zaman; Areeba Zaman; Dad J Balcoh; S Zahed Rasheed
Journal:  Cardiovasc Diagn Ther       Date:  2014-06

8.  12-Year outcome after normal myocardial perfusion SPECT in patients with known coronary artery disease.

Authors:  Machiel J M Ottenhof; Marisa C G Tjong Joe Wai; Hendrik J Boiten; Rebecca S Korbee; Roelf Valkema; Ron T van Domburg; Arend F L Schinkel
Journal:  J Nucl Cardiol       Date:  2013-08-03       Impact factor: 5.952

9.  Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction.

Authors:  Raymond Y Kwong; Hamid Sattar; Henry Wu; Gabriel Vorobiof; Vijay Gandla; Kevin Steel; Samuel Siu; Kenneth A Brown
Journal:  Circulation       Date:  2008-08-25       Impact factor: 29.690

10.  Prognostic value of myocardial perfusion scintigraphy in type 2 diabetic patients with mild, stable angina pectoris.

Authors:  Jacobijne J Wiersma; Hein J Verberne; Wik L ten Holt; Ineke M Radder; Lea M Dijksman; Berthe L F van Eck-Smit; Mieke D Trip; Jan G P Tijssen; Jan J Piek
Journal:  J Nucl Cardiol       Date:  2009-06-18       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.